{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:34:47Z","timestamp":1764714887566,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1859-1","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T13:03:04Z","timestamp":1552914184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-957X","authenticated-orcid":false,"given":"Michael","family":"Osthoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika K.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar A. F. M.","family":"Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marten","family":"Trendelenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"1859_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2012;51:1017\u201326.","journal-title":"Rheumatology."},{"key":"1859_CR2","doi-asserted-by":"crossref","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2:137\u201352.","journal-title":"J Scleroderma Relat Disord"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"e1004005","DOI":"10.1371\/journal.pcbi.1004005","volume":"11","author":"JM Mahoney","year":"2015","unstructured":"Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11:e1004005.","journal-title":"PLoS Comput Biol"},{"key":"1859_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953\u201362.","journal-title":"Arthritis Rheum"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13:538\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","volume":"73","author":"J Leffler","year":"2014","unstructured":"Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis. 2014;73:1601\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"e0114856","DOI":"10.1371\/journal.pone.0114856","volume":"10","author":"C Scambi","year":"2015","unstructured":"Scambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, La Verde V, et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study. PLoS One. 2015;10:e0114856.","journal-title":"PLoS One"},{"key":"1859_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/ard.60.6.592","volume":"60","author":"G Valentini","year":"2001","unstructured":"Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/03009742.2011.641583","volume":"41","author":"C Foocharoen","year":"2012","unstructured":"Foocharoen C, Distler O, Becker M, Muller-Ladner U, von Muhlen C, Leuchten N, et al. Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol. 2012;41:243\u20136.","journal-title":"Scand J Rheumatol"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13075-016-1147-2","volume":"18","author":"J Esposito","year":"2016","unstructured":"Esposito J, Brown Z, Stevens W, Sahhar J, Rabusa C, Zochling J, et al. The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. Arthritis Res Ther. 2016;18:246.","journal-title":"Arthritis Res Ther."},{"key":"1859_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76:270\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2014.05.013","volume":"61","author":"J Dobo","year":"2014","unstructured":"Dobo J, Schroeder V, Jenny L, Cervenak L, Zavodszky P, Gal P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol. 2014;61:69\u201378.","journal-title":"Mol Immunol"},{"key":"1859_CR14","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.112.103051","volume":"126","author":"F Orsini","year":"2012","unstructured":"Orsini F, Villa P, Parrella S, Zangari R, Zanier ER, Gesuete R, et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation. 2012;126:1484\u201394.","journal-title":"Circulation."},{"key":"1859_CR15","doi-asserted-by":"publisher","first-page":"e21338","DOI":"10.1371\/journal.pone.0021338","volume":"6","author":"M Osthoff","year":"2011","unstructured":"Osthoff M, Katan M, Fluri F, Schuetz P, Bingisser R, Kappos L, et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One. 2011;6:e21338.","journal-title":"PLoS One"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1742-2094-8-185","volume":"8","author":"G Fust","year":"2011","unstructured":"Fust G, Munthe-Fog L, Illes Z, Szeplaki G, Molnar T, Pusch G, et al. Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation. 2011;8:185.","journal-title":"J Neuroinflammation"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.1780380117","volume":"38","author":"EJ Davies","year":"1995","unstructured":"Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum. 1995;38:110\u20134.","journal-title":"Arthritis Rheum"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3899\/jrheum.090812","volume":"37","author":"LN Troelsen","year":"2010","unstructured":"Troelsen LN, Garred P, Jacobsen S. Mortality and predictors of mortality in rheumatoid arthritis--a role for mannose-binding lectin? J Rheumatol. 2010;37:536\u201343.","journal-title":"J Rheumatol"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.molimm.2014.07.003","volume":"63","author":"E Hein","year":"2015","unstructured":"Hein E, Nielsen LA, Nielsen CT, Munthe-Fog L, Skjoedt MO, Jacobsen S, et al. Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus. Mol Immunol. 2015;63:209\u201314.","journal-title":"Mol Immunol"},{"key":"1859_CR20","doi-asserted-by":"crossref","unstructured":"Miyagawa T, Asano Y, de Mestier Y, Saigusa R, Taniguchi T, Yamashita T, et al. Serum H-ficolin levels: clinical association with interstitial lung disease in patients with systemic sclerosis. J Dermatol. 2017;44:1168\u201371","DOI":"10.1111\/1346-8138.13877"},{"key":"1859_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s13075-014-0480-6","volume":"16","author":"M Osthoff","year":"2014","unstructured":"Osthoff M, Ngian GS, Dean MM, Nikpour M, Stevens W, Proudman S, et al. Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. Arthritis Res Ther. 2014;16:480.","journal-title":"Arthritis Res Ther."},{"key":"1859_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1684\/ejd.2013.2245","volume":"24","author":"K Akamata","year":"2014","unstructured":"Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, et al. Serum levels of mannose-binding lectin in systemic sclerosis: a possible contribution to the initiation of skin sclerosis in the diffuse cutaneous subtype. Eur J Dermatol. 2014;24:123\u20135.","journal-title":"Eur J Dermatol"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73:2087\u201393.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.2010.136929","volume":"70","author":"J Avouac","year":"2011","unstructured":"Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476\u201381.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754\u201363.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","unstructured":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"1859_CR27","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1859_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1046\/j.1365-3083.2002.01167.x","volume":"56","author":"RM Minchinton","year":"2002","unstructured":"Minchinton RM, Dean MM, Clark TR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol. 2002;56:630\u201341.","journal-title":"Scand J Immunol"},{"key":"1859_CR29","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1086\/590006","volume":"47","author":"DP Eisen","year":"2008","unstructured":"Eisen DP, Dean MM, Boermeester MA, Fidler KJ, Gordon AC, Kronborg G, et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis. 2008;47:510\u20136.","journal-title":"Clin Infect Dis"},{"key":"1859_CR30","doi-asserted-by":"publisher","first-page":"e0134107","DOI":"10.1371\/journal.pone.0134107","volume":"10","author":"M Osthoff","year":"2015","unstructured":"Osthoff M, Dean MM, Baird PN, Richardson AJ, Daniell M, Guymer RH, et al. Association study of mannose-binding lectin levels and genetic variants in lectin pathway proteins with susceptibility to age-related macular degeneration: a case-control study. PLoS One. 2015;10:e0134107.","journal-title":"PLoS One"},{"key":"1859_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/infdis\/jis396","volume":"206","author":"EA Ouf","year":"2012","unstructured":"Ouf EA, Ojurongbe O, Akindele AA, Sina-Agbaje OR, Van Tong H, Adeyeba AO, et al. Ficolin-2 levels and FCN2 genetic polymorphisms as a susceptibility factor in schistosomiasis. J Infect Dis. 2012;206:562\u201370.","journal-title":"J Infect Dis"},{"key":"1859_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard.62.9.901","volume":"62","author":"G Valentini","year":"2003","unstructured":"Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003;62:901\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.humimm.2013.04.011","volume":"74","author":"DC Kilpatrick","year":"2013","unstructured":"Kilpatrick DC, St Swierzko A, Matsushita M, Domzalska-Popadiuk I, Borkowska-Klos M, Szczapa J, et al. The relationship between FCN2 genotypes and serum ficolin-2 (L-ficolin) protein concentrations from a large cohort of neonates. Hum Immunol. 2013;74:867\u201371.","journal-title":"Hum Immunol"},{"key":"1859_CR34","doi-asserted-by":"publisher","first-page":"e0159878","DOI":"10.1371\/journal.pone.0159878","volume":"11","author":"SL Ashley","year":"2016","unstructured":"Ashley SL, Xia M, Murray S, O'Dwyer DN, Grant E, White ES, et al. Six-SOMAmer index relating to immune, protease and angiogenic functions predicts progression in IPF. PLoS One. 2016;11:e0159878.","journal-title":"PLoS One"},{"key":"1859_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/cei.12459","volume":"179","author":"ML Metzger","year":"2015","unstructured":"Metzger ML, Michelfelder I, Goldacker S, Melkaoui K, Litzman J, Guzman D, et al. Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis. Clin Exp Immunol. 2015;179:256\u201364.","journal-title":"Clin Exp Immunol"},{"key":"1859_CR36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1165\/rcmb.2013-0152OC","volume":"49","author":"HG Leach","year":"2013","unstructured":"Leach HG, Chrobak I, Han R, Trojanowska M. Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury. Am J Respir Cell Mol Biol. 2013;49:1093\u2013101.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1859_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molimm.2006.04.002","volume":"44","author":"ML Jensen","year":"2007","unstructured":"Jensen ML, Honore C, Hummelshoj T, Hansen BE, Madsen HO, Garred P. Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol Immunol. 2007;44:856\u201365.","journal-title":"Mol Immunol"},{"key":"1859_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.autrev.2008.12.019","volume":"8","author":"H Waldner","year":"2009","unstructured":"Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev. 2009;8:400\u20134.","journal-title":"Autoimmun Rev"},{"key":"1859_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.7326\/0003-4819-86-4-394","volume":"86","author":"R Salerni","year":"1977","unstructured":"Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med. 1977;86:394\u20139.","journal-title":"Ann Intern Med"},{"key":"1859_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/ard.33.5.473","volume":"33","author":"DG Scott","year":"1974","unstructured":"Scott DG, Rowell NR. Immunohistological studies of the kidney in systemic lupus erythematosus and systemic sclerosis using antisera to IgG, C3, fibrin, and human renal glomeruli. Ann Rheum Dis. 1974;33:473\u201381.","journal-title":"Ann Rheum Dis"},{"key":"1859_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-71-4-753","volume":"71","author":"DM Kay","year":"1969","unstructured":"Kay DM, Tuffanelli DL. Immunofluorescent techniques in clinical diagnosis of cutaneous disease. Ann Intern Med. 1969;71:753\u201362.","journal-title":"Ann Intern Med"},{"key":"1859_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","volume":"18","author":"M Okroj","year":"2016","unstructured":"Okroj M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016;18:267.","journal-title":"Arthritis Res Ther"},{"key":"1859_CR43","doi-asserted-by":"publisher","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","volume":"95","author":"A Devresse","year":"2016","unstructured":"Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, et al. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine. 2016;95:e4459.","journal-title":"Medicine."},{"key":"1859_CR44","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/art.22564","volume":"56","author":"C Honore","year":"2007","unstructured":"Honore C, Hummelshoj T, Hansen BE, Madsen HO, Eggleton P, Garred P. The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum. 2007;56:1598\u2013607.","journal-title":"Arthritis Rheum"},{"key":"1859_CR45","first-page":"402","volume":"27","author":"H Sprott","year":"2000","unstructured":"Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M, et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol. 2000;27:402\u20134.","journal-title":"J Rheumatol"},{"key":"1859_CR46","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1600-6143.2011.03887.x","volume":"12","author":"P Pol van der","year":"2012","unstructured":"van der Pol P, Schlagwein N, van Gijlswijk DJ, Berger SP, Roos A, Bajema IM, et al. Mannan-binding lectin mediates renal ischemia\/reperfusion injury independent of complement activation. Am J Transplant. 2012;12:877\u201387.","journal-title":"Am J Transplant"},{"key":"1859_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4049\/jimmunol.175.1.541","volume":"175","author":"MC Walsh","year":"2005","unstructured":"Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol. 2005;175:541\u20136.","journal-title":"J Immunol"},{"key":"1859_CR48","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/eurheartj\/ehp597","volume":"31","author":"M Trendelenburg","year":"2010","unstructured":"Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2010;31:1181\u20137.","journal-title":"Eur Heart J"},{"key":"1859_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/art.22302","volume":"56","author":"LN Troelsen","year":"2007","unstructured":"Troelsen LN, Garred P, Madsen HO, Jacobsen S. Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum. 2007;56:21\u20139.","journal-title":"Arthritis Rheum"},{"key":"1859_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1084\/jem.20041431","volume":"201","author":"S Saevarsdottir","year":"2005","unstructured":"Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med. 2005;201:117\u201325.","journal-title":"J Exp Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1859-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:29:42Z","timestamp":1584404982000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1859-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"28 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approved by the Ethics Committee at participating Basel and Zurich University EUSTAR centers, patients were required to provide informed written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OD has\/had consultancy relationship and\/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espeRare foundation, Genentech\/Roche, GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Serodapharm, and UCB in the area of potential treatments of scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis licensed. MO, IH, SJ, VJ, and UAW declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"76"}}